Study identifier:D133FR00118
ClinicalTrials.gov identifier:NCT03082976
EudraCT identifier:N/A
CTIS identifier:N/A
PREDICT: Prevalence of BRCA1 and BRCA2 mutations in Ovarian Cancer patients in the Gulf region. A prospective, multi-centre, epidemiological observational study designed to evaluate the prevalence of BRCA1 and BRCA2 mutations in current and newly diagnosed ovarian cancer patients across different countries in the Gulf region. This study study will also describe the epidemiological features for the disease for the enrolled patients.
ovarian cancer
N/A
No
-
Female
108
Observational
18 Years +
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jul 2020 by AstraZeneca
AstraZeneca
-
A prospective, multi-centre, epidemiological observational study designed to evaluate the prevalence of BRCA1 and BRCA2 (BReast CAncer gene) mutations in current and newly diagnosed ovarian cancer patients across different countries in the Gulf region. This study will also describe the epidemiological features for the disease for the enrolled patients.
Location
Location
AL AIN, United Arab Emirates
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.